|Bid||2.83 x 3000|
|Ask||2.89 x 800|
|Day's Range||2.69 - 2.98|
|52 Week Range||1.63 - 30.00|
|PE Ratio (TTM)||0.15|
|Earnings Date||Nov 27, 2017 - Dec 1, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.00|
NEW YORK, NY / ACCESSWIRE / May 23, 2018 / U.S. markets fell Tuesday on geopolitical concerns after President Trump stated he was not happy with the current U.S. – China trade talks. The Dow Jones Industrial ...
Forward Pharma A/S (FWP) (“We” or “Forward” or the “Company”), today announced the filing of a notice of appeal of the decision of the Opposition Division of the European Patent Office (the “EPO”) that revoked EP2801355 (the “’355 patent”), written reasons for which were received on March 22, 2018. The notice was filed to the Technical Board of Appeal (the “TBA”) of the EPO. “With the notice of appeal filed, we officially initiate the process to get the decision of the Opposition Division overturned and have the ‘355 patent reinstated,” said Dr. Claus Bo Svendsen, Chief Executive Officer of Forward.
COPENHAGEN, Denmark, April 30, 2018-- Forward Pharma A/S, today reported financial results for the year ended December 31, 2017. Net income for the year ended December 31, 2017 was $917.1 million, or $2.30 ...
Stocks, such as SandRidge Mississippian Trust I and Hudson Technologies, are trading at a value below what they may actually be worth. There’s a few ways you can determine howRead More...
Full Time Employees: 5
Forward Pharma A/S operates as a biopharmaceutical company. The company focuses on developing FP187, a proprietary formulation of dimethyl fumarate used for the treatment of various inflammatory and neurological indications. Forward Pharma A/S was founded in 2005 and is headquartered in Copenhagen, Denmark.